Study #2021-0166
AN OPEN-LABEL, MULTICENTER, PHASE IB/II TRIALEVALUATING THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND EFFICACY OFMOSUNETUZUMAB (BTCT4465A) IN COMBINATIONWITH POLATUZUMAB VEDOTIN IN PATIENTS WITH BCELLNON-HODGKIN LYMPHOMA
MD Anderson Study Status
Enrolling
Treatment Agent
Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab
Description
This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of intravenous mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL), and in participants with follicular lymphoma (FL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL. In addition, subcutaneous mosunetuzumab in combination with polatuzumab vedotin will be evaluated in participants with at least 2 prior lines of systemic therapy for the treatment of R/R mantle cell lymphoma (MCL).
Information and next steps
Disease:
B-cell Non-Hodgkin Lymphoma
Study phase:
I/II
Physician name:
Luhua Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.